Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Assertio Holdings, Inc.NASDAQ: ASRT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $18.86M (cash outflow) rose 39.3% year over year, ahead of the +16.6% change in trailing-twelve-month net income. Sequentially, it rose 58.1% from the prior quarter.

Context

  • Net income amounted to 25.6% of revenue in FY2025, up 8.3 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$10.5M (-65.4%) for the fiscal year ending Dec 2026, a slowdown from the +40.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.86M+58.1% QoQ
Last fiscal yearDec 2025
-$30.38M+40.7% YoY
LTMMar 2026
-$35.69M+16.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.3%-85.9%-125.2 pp
1 year+40.7%-65.4%-106.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(30.38M) USD
Year-over-year change
-40.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +16.6% is the 4th highest of 10, against a peer median of +1.9%.
  • Net income amounts to 34.9% of revenue for ASRT, versus a peer median of 107.2%.
ASRT Competitors
Net Income for ASRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$124.31M USD-5.5%+25.1%1360.6%
FBIOFortress Biotech, Inc.LTM Mar 2026$102.15M USD+215.2%-46.4%154.4%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$78.34M USD+28.7%+2.0%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$77.27M USD-7.7%+35.7%—
INCRInterCure Ltd.LTM Jun 2025₪70.93M ILS+8.1%—29.2%
LUNGPulmonx CorporationLTM Mar 2026$53.21M USD-6.8%-2.9%60.1%
XBITXBiotech Inc.LTM Mar 2026$40.16M USD+1.9%+11.4%—
VXRTVaxart, Inc.LTM Mar 2026$37.1M USD+163.8%—14.5%
ASRTAssertio Holdings, Inc.LTM Mar 2026$35.69M USD+16.6%—34.9%
NTRBNutriband Inc.LTM Apr 2026$8.08M USD-19.0%+22.4%448.4%
Peer median (excluding ASRT) —+1.9%+11.4%107.2%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Depreciation & Amortization29.08M33.4M28.23M25.83M30.01M
Deferred Income Tax0(80.38M)76.2M00
Stock-Based Compensation3.55M7.5M9.16M5.01M3.45M
Change in Working Capital(31.29M)(13.01M)140K5.2M(45.33M)
Accounts Receivables(11K)(996K)48.67M(6.46M)(65.99M)
Inventory4.27M(6.59M)(4.97M)(9.58M)9.68M
Accounts Payables(28.7M)(10.11M)(29.35M)(1.26M)(13.29M)
Other Working Capital(6.85M)4.69M(14.21M)22.5M24.27M
Other Non-Cash Items5.48M21.46M267.82M11.95M14.07M
Operating Cash Flow5.52M78.6M49.6M26.41M(28.18M)
Capital Expenditures(53K)(274K)(628K)00
Acquisitions (Net)(18.47M)(42.4M)1.53M00
Purchases of Investments000(98.61M)(119.2M)
Sales of Investments002.19M49.69M115.38M
Other Investing Activities0000(8.17M)
Investing Cash Flow(18.53M)(42.67M)3.1M(48.91M)(11.99M)
Debt Repayment(9.84M)(750K)(10.5M)00
Common Stock Issued44.86M7.02M000
Common Stock Repurchased(418K)(838K)(7.9M)(350K)0
Dividends Paid00000
Other Financing Activities(5.58M)(13.23M)(25.8M)0(189K)
Financing Cash Flow29.03M(7.79M)(44.2M)(350K)(189K)
Effect of Forex Changes00000
Net Change in Cash16.02M28.13M8.5M(22.85M)(40.36M)
Free Cash Flow5.47M78.32M48.98M26.41M(28.18M)

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.